Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 9, Pages 1902-1909
Publisher
Springer Nature
Online
2013-04-02
DOI
10.1038/leu.2013.95
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria.
- (2017) F. Samaniego et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
- (2012) C Visco et al. LEUKEMIA
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
- (2011) Francisco J. Hernandez-Ilizaliturri et al. CANCER
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
- (2011) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials
- (2011) Liat Vidal et al. JNCI-Journal of the National Cancer Institute
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
- (2009) Liang Zhang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
- (2009) A. G. Ramsay et al. BLOOD
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- The incidence, natural history, biology, and treatment of transformed lymphomas
- (2009) S. H. Bernstein et al. Hematology-American Society of Hematology Education Program
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started